MedTrace Logo

Intranasal Bevacizumab for HHT-Related Epistaxis

NCT02389959 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-01

Study results available
· View outcomes & findings →

Summary

This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.

Conditions

  • HHT
  • Hereditary Hemorrhagic Telangiectasia
  • Epistaxis
  • Nose Bleeds
  • Nasal Bleeding

Interventions

DRUG

Bevacizumab

Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose

DRUG

Placebo (Saline)

4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control

Sponsors & Collaborators

Principal Investigators

  • Peter H Hwang, MD · Stanford University, Department of Otolaryngology- Head and Neck Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-04
Primary Completion
2020-01-23
Completion
2020-01-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02389959 on ClinicalTrials.gov